Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy

Colleen K Spees; Kelly J Kelleher; Ronney Abaza; Steven K Clinton

doi:10.1016/j.eucr.2015.01.002

Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy

Urol Case Rep. 2015 Feb 7;3(2):21-3. doi: 10.1016/j.eucr.2015.01.002. eCollection 2015 Mar.

Authors

Colleen K Spees¹, Kelly J Kelleher², Ronney Abaza³, Steven K Clinton⁴

Affiliations

¹ Medical Dietetics and Health Sciences, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
² College of Public Health, The Ohio State University, Columbus, OH, USA; Research Institute at Nationwide Children's Hospital, Columbus, OH, USA; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
³ Department of Urology, The Ohio State University College of Medicine, Columbus, OH, USA; Robotic Urologic Surgery, OhioHealth Dublin Methodist Hospital, Dublin, OH, USA.
⁴ Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Department of Urology, The Ohio State University College of Medicine, Columbus, OH, USA; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.

Abstract

Li-Fraumeni Syndrome (LFS) is an autosomal dominant genetic disorder associated with mutations in the TP53 gene and characterized by a propensity to develop a variety of malignancies resulting in a shortened lifespan. We report a case of prostate cancer in a 50 year old male with LFS. Experimental studies suggest that TP53 mutations in prostate cancer are associated with therapeutic resistance to radiation, chemotherapy, and anti-androgens, implying that LFS men may experience more aggressive cancer biology with implications for therapeutic decisions. The potential of prostate cancer to develop earlier in LFS favors institution of screening at earlier ages.

Keywords: Li-Fraumeni Syndrome; Prostate cancer; TP53; p53.

Publication types

Case Reports

Grants and funding

UL1 TR001070/TR/NCATS NIH HHS/United States